Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
5/28/2026, 12:00:00 AM
CVS Caremark announced it will add Lilly's obesity drugs Foundayo and Zepbound to its preferred formularies, significantly expanding patient access; high impact due to increased market share expected
Korean Translation
주요 의약품 관리 업체(PBM)인 CVS 케어마크가 릴리의 비만 치료제 파운다요(Foundayo)와 젭바운드(Zepbound)를 선호 의약품 목록에 추가하여 접근성을 확대함. 시장 점유율 확대에 따른 높은 시장 영향이 예상됨
Related Recent Events
Target Corp (TGT) · Earnings Release
Target's Q2 2026 earnings release is set for August 19, 2026; low importance is estimated as the date announcement itself typically has a market impact of less than 5%, scheduled.
8/19/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
AST SpaceMobile Inc (ASTS) · Earnings Release
Q2 2026 earnings release and conference call for August 10, 2026, which is expected to have a medium impact by providing key financial updates, scheduled.
8/10/2026, 12:00:00 AM
Chevron Corp (CVX) · Earnings Release
Q2 2026 earnings release is scheduled for August 7, 2026; analysts forecast a significant increase in earnings due to higher oil prices and full integration of Hess assets. Market impact is estimated at Medium (5%) as earnings are a primary driver of stock volatility, scheduled.
8/7/2026, 12:00:00 AM
Akamai Technologies Inc (AKAM) · Earnings Release
Q2 2026 earnings release scheduled for 2026-08-06. Analysts forecast EPS of around $1.60 forecasted. High importance estimated due to the 26% price movement in the previous earnings release scheduled.
8/6/2026, 12:00:00 AM
Consolidated Edison Inc. (ED) · Earnings Release
Q2 2026 earnings release on 2026-08-06 is scheduled. Low importance is estimated as the primary market impact occurs on the release date, scheduled.
8/6/2026, 12:00:00 AM